
Claims

1. A compound of formula (I)



(I)

wherein

R^1 is hydrogen or alkyl;

R^2 is hydrogen, halogen, alkyl, alkoxy or haloalkyl;

R^3 is hydrogen, alkyl or halogen;

A^1 is -N- or -C-; and

A^2 is -CH- or -O-; with the proviso that if A^1 is -N-, then A^2 is -CH-; and the proviso that if A^1 is -C-, then A^2 is -O-;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, wherein R^1 is hydrogen or methyl.

3. A compound according to claim 1 or 2, wherein R^1 is hydrogen.

4. A compound according to any one of claims 1 to 3, wherein R^2 is hydrogen, alkyl, alkoxy or haloalkyl.

5. A compound according to any one of claims 1 to 4, wherein R^2 is hydrogen, methyl, methoxy or trifluoromethyl.

6. A compound according to any one of claims 1 to 4, wherein R^3 is alkyl or halogen.

7. A compound according to any one of claims 1 to 6, wherein R^3 is methyl or chloro.

8. A compound according to any one of claims 1 to 7, wherein A_1 is -N-, and A^2 is -CH-.

9. A compound according to any one of claims 1 to 7, wherein A_1 is -C-, and A_2 is -O-.

10. A compound of formula (I) according to any one of claims 1 to 9 selected from

rac-7-(4-azaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;

rac-7-(4-azaspiro[2.5]octan-7-yl)-2-(8-methoxy-2-methyl-imidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;

rac- 7-(4-azaspiro[2.5]octan-7-yl)-2-[2-methyl-8-(trifluoromethyl)imidazo[1,2-b]pyridazin-6-yl]pyrido[1,2-a]pyrimidin-4-one;

rac-7-(4-azaspiro[2.5]octan-7-yl)-2-(2,7-dimethyloxazolo[5,4-b]pyridin-5-yl)pyrido[1,2-a]pyrimidin-4-one; and


rac-7-(4-azaspiro[2.5]octan-7-yl)-2-(2-chloroimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one;

or a racemic mixture or its corresponding enantiomers thereof,

or a pharmaceutically acceptable salt thereof.


11. A process for the preparation of a compound according to any one of claims 1 to 9, comprising at least one of the following steps:

(a) the reaction of a compound of formula (B1)




(B1)

with a compound of formula (B2)




(B2)

in a suitable solvent in the presence of a base and a suitable palladium catalyst, wherein n is 0 or 1, X is O-tosylate, O-triflate, O-mesylate or halogen, and wherein in $-B(OR)_2$ each R is independently selected from hydrogen and alkyl, or $-B(OR)_2$ is optionally substituted dioxaborolanyl, to arrive at a compound of fomula (B3)



(B3)

(b) the reaction of the compound of formula (B3), in a suitable solvent and in presence of an acid to yield the compound of formula (I)



(I)

wherein in the process R^1, R^2, R^3, A_1 and A_2 are as defined in any one of claims 1 to 13, and PG is a protecting group.

12. A compound according to any one of claims 1 to 10, when manufactured according to a process of claim 11.

13. A compound according to any one of claims 1 to 10 for use as therapeutically active substance.

14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a therapeutically inert carrier.

15. A compound according to any one of claims 1 to 10 for use in the treatment or prophylaxis of a neurodegenerative disease, in particular Huntington's disease.

16. The use of a compound according to any one of claims 1 to 10 for the treatment or prophylaxis of a neurodegenerative disease, in particular Huntington's disease.

17. The use of a compound according to any one of claims 1 to 10 for the preparation of a medicament for the treatment or prophylaxis of a neurodegenerative disease, in particular Huntington's disease.

18. A method for the treatment or prophylaxis of a neurodegenerative disease, in particular Huntington's disease, which method comprises administering an effective amount of a compound according to any one of claims 1 to 10 to a patient in need thereof.

***